Research & Development
Dizlin’s research and development resources are currently focusing on products for treatment of Parkinson’s disease.
Product portfolio – Dizlin is developing new products for treatment of Parkinson’s disease (PD). Clinical trials on two of these products , Infudopa SubC© and Infudopa IntraV© , which will serve as a basis for a registration in Europe, are either being performed or will be undertaken during 2020. According to the present time-schedule, an application for registration of Infudopa IntraV© will be submitted in 2020. Development of additional treatment alternatives for patients with PD is ongoing.
New way of treatment – First-line treatment of PD has since long been per oral administration of the dopamine precursor levodopa in combination with an enzyme inhibitor, carbidopa, preventing the conversion of levodopa to dopamine outside the brain. In late stages of the disorder, the fluctuating serum levels of levodopa following this regimen however often results in rapid switches between reduced mobility and involuntary movements, so called on-off. Infudopa©, is the umbrella term for infusion solutions developed by Dizlin that contain levodopa and carbidopa. Infudopa© may be administered through intravenous injection, short-term intravenous infusion (Infudopa® IntraV) and long-term continuous subcutaneous infusion (Infudopa© SubC), respectively. By providing rapid and stable serum levels of levodopa, these treatments will improve the condition of subjects suffering from on-off as well as of those requiring rapid symptom relief from marked hypokinesia. In the near future, patients with PD may hence be treated in the same way as insulin-dependent diabetes patients. i.e. through continuous subcutaneous infusion using a small pump.
Market demand – PD is the second largest neurodegenerative disease (after Alzheimer’s disease) affecting the Central Nervous System (CNS) and is growing rapidly throughout the world along with a growing population and an increasing share of elderly in the population. Infudopa© is targeting PD-patients suffering from both moderate and severe PD. Infudopa© has the potential to become an important treatment for PD patients suffering from on-off symptoms.
Parkinson’s disease (PD) is the second largest neurodegenerative disease (after Alzheimer’s disease) affecting the Central Nervous System (CNS) and PD is growing rapidly along with an increasing share of elderly in the population.
Infudopa© is a portfolio of infusion solutions containing levodopa and carbidopa, which allows for injection, short-term continuous intravenous infusion and short-term continuous subcutaneous infusion.
A clinical trial is currently being performed on Infudopa©, which should be enough comprehensive to serve as a basis for a registration in Europe. The trial is scheduled to be finalized end Q4 2019 or Q1 2020.
“I have an ethical responsibility to contribute to Infudopa© becoming available to patients suffering from Parkinson’s disease”
– Arvid Carlsson – Nobel Prize winner